ACTI.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 11:19):

Stats
Today's Volume	403 159
Average Volume	895 368
Market Cap	209.26M
EPS	SEK0 ( 2024-02-07 )
Next earnings date	( SEK0 ) 2024-05-07
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-2.91
ATR14	SEK0.00500 (0.90%)

Volume Correlation

Long: -0.30 (neutral)

Short: 0.29 (neutral)

Signal:(51.3) Neutral

Active Biotech AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Active Biotech AB (publ) Correlation - Currency/Commodity

-0.66
( moderate negative )

-0.69
( moderate negative )

0.00
( neutral )

0.52
( weak )

Active Biotech AB (publ) Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-1.70M (0.00 %)
EPS:	SEK-0.170

Q4	2023
Revenue:	SEK0
Gross Profit:	SEK-400 000 (0.00 %)
EPS:	SEK-0.0438

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-400 000 (0.00 %)
EPS:	SEK-0.0359

Q2	2023
Revenue:	SEK0
Gross Profit:	SEK-400 000 (0.00 %)
EPS:	SEK-0.0380

Financial Reports:

No articles found.

Active Biotech AB (publ)

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.